ReViral's oral RSV candidate meets in Phase IIa

ReViral Ltd. (Stevenage, U.K.) said lead candidate RV521 met the primary and all secondary endpoints in a Phase IIa respiratory syncytial virus (RSV) challenge trial in healthy adult volunteers. CEO Eddy Littler told BioCentury the company plans to start a Phase IIa trial of the oral small molecule RSV fusion inhibitor in infants this summer, with further studies in adults expected to start in 2020.

The double-blind, placebo-controlled, U.K. trial evaluated twice-daily 200 and 350 mg doses of oral RV521 for five days in 66 subjects who were inoculated intranasally with RSV. Both doses of RV521 significantly reduced viral load at day 12, the primary endpoint, and significantly reduced mean total mucus weight and clinical symptoms as measured by total symptom diary score, both secondary endpoints, vs. placebo. No treatment-related serious adverse events were reported...